$9.950
-0.403 (-4.05%)收盘时
ICCC 资讯
ICCC 事件
Nasdaq Falls 0.4%, WTI Crude Rises to $93
Escalating geopolitical tensions and a more wobbly AI trade was the story of the day on Monday, with Tech-heavy Nasdaq Composite following 0.4% and S&P 500 finishing the day down by a decimal.WTI crude oil was up for the third consecutive day, rising above $93 per barrel as attack on a Saudi airport by Iran-backed Houthi militia - followed by a strong rebuke of the strike from the White House - threatened to draw the US into the Saudi-Yemen conflict and further destabilize the Middle East. Energy was the best-performing sector in the S&P 500, followed closely by Consumer Staples stocks.Technology was the worst performing area of the market, as the basket of stocks most closely associated with the AI buildout drove the retreat. Communication Equipment and Semiconductor Equipment and Materials saw outsized selling, with stocks like Ciena, Lumentum, Corning, and Sandiskregistering some of the biggest daily declines in the S&P 500 on Monday.In the opening hour of the evening session, index futures are slightly lower, with S&P e-minis down by a decimal and the Nasdaq 100 contract off by 0.2%. Q3 earnings season kicks off on Tuesday with high-profile earnings from large financials, including JPMorgan Chaseand Goldman Sachs.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Nurix Therapeuticsup 4.1%ALSO HIGHER -Navitas Semiconductorup 4.3% after announcing a partnership with Nvidia on power delivery boardFormFactorup 3.6% after announcing a $300M investment from TeraDyneImmuCellup 2.2% after Q3 revenue pre-announcementLOWER -Syndax Pharmaceuticalsdown 19.4% after idiopathic pulmonary fibrosis study did not meet endpointSix Flags Entertainmentdown 11.9% after report of rollercoaster fatality in Georgia
ImmuCell Reports Q3 Sales of $8.0 Million, Up 46%
"Total sales for the three months ended September 30, 2026 were $8.0 million, a 46.0% increase compared to the three months ended September 30, 2025. Domestic sales were $6.9 million, a 29.2% increase compared to 2025," said Timothy Fiori, CFO of ImmuCell. "We are pleased with the sales results experienced during the third quarter of 2026, recognizing our comparative sales growth was aided, in part, by depressed sales levels in the third quarter of 2025 caused by high distributor purchases in the second quarter of 2025. Total sales for the nine months ended September 30, 2026 were $25.6 million, a 27.8% increase compared to the nine months ended September 30, 2025."
ImmuCell Q2 Sales Increase 11.5% to $7.2 Million
"Total sales for the three months ended June 30, 2026 were $7.2 million, an 11.5% increase compared to the three months ended June 30, 2025, driven by a 27.7% increase in domestic sales compared to 2025," said Timothy Fiori, CFO of ImmuCell. "Our growth in the second quarter is particularly significant given the challenging comparison with the second quarter of 2025, when ImmuCell recorded substantial sales from distributors replenishing inventory following an extended period of backorders. International sales in the three months ended June 30, 2026 declined $0.6 million, or 38.9% compared to 2025; however, we believe that end-customer demand remains strong, particularly in Canada. Total sales for the six months ended June 30, 2026 were $17.5 million, a 20.9% increase compared to the six months ended June 30, 2025."
ImmuCell Reports Preliminary FY25 Revenue of $27.6M
Reports preliminary FY25 revenue $27.6M. "Sales for the quarter exceeded our expectations and show that we continue to make progress rebuilding our market position after a period of supply challenges," commented Olivier te Boekhorst, president and CEO of ImmuCell. "This was one of our highest sales quarters ever, without tailwinds from catching up on backorders. Our international business showed a decline, largely due to order timing. We are highly encouraged by the strong growth of our Tri-Shield product line, which reflects the migration from Dual-Force products and the acquisition of new dairy and beef customers seeking protection for their calves."
ImmuCell Pauses Re-Tain Investment, Increases First Defense Sales Force by 50%
ImmuCell Corporation announced that it received an Incomplete Letter from the FDA on December 23 for its Re-Tain New Animal Drug Application, or NADA, and simultaneously that it is increasing its First Defense field sales force by 50% and expanding its First Defense manufacturing capabilities. In seeking FDA approval to bring its innovative Re-Tain product to market, ImmuCell received Complete Letters from the FDA for four of the five Technical Sections required for NADA approval. It pursued a two-pronged manufacturing approach to reduce capital expenditure and limit technical risk for the remaining fifth Technical Section pertaining to manufacturing. ImmuCell manufactured the active pharmaceutical ingredient using a proprietary process in its own facility and hired an experienced contract manufacturer with FDA approvals for animal health products for the aseptic filling of the product into syringes. ImmuCell passed FDA inspection of its own facility in 2024. It is ImmuCell's understanding that the FDA is now declining to approve the NADA because the contract manufacturer has not satisfactorily addressed inspectional deficiencies. After considering the practical implications of the resulting delays, including the pending expiration of ImmuCell's contract with the manufacturer in March 2026, ImmuCell has decided to pause further investment in Re-Tain and increase its investment in its market leading First Defense franchise, which it believes to have significant revenue and profit growth capacity. ImmuCell will complete ongoing investigational studies with Re-Tain to assess opportunities for an improved set of claims for preventing and treating mastitis in dairy cows. It will seek to license the product to interested parties or, depending on the outcome of the studies, may seek to partner with a global manufacturer. Neither approach would require further capital investment or in-house manufacturing capability, meaning that ImmuCell will prioritize cash and other resources for maximizing the value of its market leading First Defense franchise.
相关文章
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。